共 50 条
- [41] Tofacitinib Versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis [ORCHID]: A Prospective, Open-Label, Randomized, Pilot Study JOURNAL OF CROHNS & COLITIS, 2024, 18 (02): : 300 - 307
- [43] Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (11): : 2478 - 2485
- [45] Optimization of Oral Mesalamine Therapy Leads to Clinical Improvement in Mild to Moderate Ulcerative Colitis AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S488 - S488
- [47] MMX mesalamine for the treatment of active mild-to-moderate ulcerative colitis: An evidence-based medicine analysis AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S431 - S432
- [48] Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids JOURNAL OF CROHNS & COLITIS, 2014, 8 (11): : 1523 - 1528
- [50] Once- or twice-daily MMX™ mesalamine for the maintenance of remission of mild or moderate ulcerative colitis AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S463 - S463